NASDAQ: FHTXFoghorn Therapeutics Inc Stock
$4.20-0.05 (-1.18%)
Updated Apr 30, 2025
FHTX Price
$4.20
Fair Value Price
N/A
Market Cap
$233.57M
52 Week Low
$2.95
52 Week High
$10.25
P/E
-2.66x
P/B
-5.13x
P/S
11.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.60M
Earnings
-$86.62M
Gross Margin
100%
Operating Margin
-383.24%
Profit Margin
-383.2%
Debt to Equity
-7.24
Operating Cash Flow
-$100M
Beta
1.47
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FHTX Overview
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting genetically determined dependencies within the chromatin regulatory system using its Gene Traffic Control platform. Foghorn Therapeutics has a research collaborationsand license agreements with Merck and Loxo Oncology.the company was incorporated in 2015 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FHTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FHTX
Ranked#77 of 462
Ranked#77 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important FHTX news, forecast changes, insider trades & much more!
FHTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FHTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FHTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FHTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
FHTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more FHTX due diligence checks available for Premium users.
Valuation
FHTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.66x
Industry
-162.28x
Market
29.18x
FHTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.13x
Industry
4.45x
FHTX's financial health
Profit margin
Revenue
$2.9M
Net Income
-$19.5M
Profit Margin
-682.9%
FHTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FHTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$284.0M
Liabilities
$329.5M
Debt to equity
-7.24
FHTX's short-term assets ($249.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FHTX's long-term liabilities ($262.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FHTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FHTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.5M
Investing
$22.3M
Financing
$4.0k
FHTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FHTX vs Biotech Stocks
Foghorn Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.